Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161)

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
362kB

Item Type:Article
Title:Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161)
Creators Name:Sinn, M. and Nicolaou, A. and Ricke, J. and Podrabsky, P. and Seehofer, D. and Gebauer, B. and Pech, M. and Neuhaus, P. and Doerken, B. and Riess, H. and Hildebrandt, B.
Abstract:BACKGROUND: Hepatic arterial infusion (HAI) of chemotherapy requires the implantation of a transcatheter application system which is traditionally performed by surgery. This procedure, but particularly the adjacent drug application via pump or port is often hampered by specific complications and device failure. Interventionally implanted port catheter systems (IIPCS) facilitate the commencement of HAI without need for laparatomy, and are associated with favorable complication rates. We here present an evaluation of the most important technical endpoints associated with the use of IIPCS for HAI in patients with primary liver cancers. METHODS: 70 patients (pts) with hepatocellular (HCC, n=33) and biliary tract cancer (BTC, n=37) were enrolled into a phase II -study. Of those, n=43 had recurrent disease and n=31 suffered from liver-predominant UICC-stage IVb. All pts were provided with IIPCSs before being treated with biweekly, intraarterial chemotherapy (oxaliplatin, 5-Flourouracil, folinic acid). The primary objective of the trial was defined as evaluation of device-related complications and port duration. RESULTS: Implantation of port catheters was successful in all patients. Mean treatment duration was 5,8 months, and median duration of port patency was not reached. Disease-progression was the most common reason for treatment discontinuation (44 pts., 63%), followed by chemotherapy-related toxicity (12 pts., 17%), and irreversible device failure (5 pts., 7%). A total of 28 port complications occurred in 21 pts (30%). No unexpected complications were observed. CONCLUSIONS: HAI via interventionally implanted port catheters can be safely applied to patients with primary liver tumors far advanced or/and pretreated.
Keywords:Hepatic Arterial Infusion, Infusions, Intra-Arterial, Liver Neoplasms, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocellular Carcinoma, Natriumfolinate, 5-Fluorouracil, Oxaliplatin
Source:BMC Gastroenterology
ISSN:1471-230X
Publisher:BioMed Central (U.K.)
Volume:13
Page Range:125
Date:9 August 2013
Official Publication:https://doi.org/10.1186/1471-230X-13-125
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library